Wesbanco Bank Inc. Acquires 23,000 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Wesbanco Bank Inc. boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 41.1% in the first quarter, Holdings Channel.com reports. The fund owned 79,000 shares of the biopharmaceutical company’s stock after acquiring an additional 23,000 shares during the quarter. Wesbanco Bank Inc.’s holdings in Catalyst Pharmaceuticals were worth $1,956,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Louisiana State Employees Retirement System bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter worth $1,268,000. BTC Capital Management Inc. increased its stake in Catalyst Pharmaceuticals by 5.9% in the 1st quarter. BTC Capital Management Inc. now owns 19,795 shares of the biopharmaceutical company’s stock worth $490,000 after buying an additional 1,100 shares during the period. Assenagon Asset Management S.A. increased its stake in Catalyst Pharmaceuticals by 15.8% in the 1st quarter. Assenagon Asset Management S.A. now owns 160,615 shares of the biopharmaceutical company’s stock worth $3,977,000 after buying an additional 21,877 shares during the period. Campbell Newman Asset Management Inc. lifted its holdings in Catalyst Pharmaceuticals by 1.7% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 92,476 shares of the biopharmaceutical company’s stock valued at $2,290,000 after buying an additional 1,559 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Catalyst Pharmaceuticals by 392.9% during the 1st quarter. SG Americas Securities LLC now owns 161,552 shares of the biopharmaceutical company’s stock valued at $4,000,000 after buying an additional 128,776 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 0.3%

NASDAQ:CPRX opened at $31.50 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56. The firm has a 50 day moving average of $30.38 and a 200 day moving average of $26.20. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Citigroup cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $35.00 to $31.50 in a research note on Friday, May 8th. Finally, Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).